BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 10, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stedesa eslicarbazepine acetate regulatory update

FDA issued a complete response letter for an NDA from Sepracor Inc. for Stedesa eslicarbazepine as adjunctive therapy to treat partial-onset seizures in adults with epilepsy....

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >